Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-651-8851
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees62
Next Earnings DateN/A
OptionableNot Optionable
Fulcrum Therapeutics (NASDAQ:FULC) Frequently Asked Questions
What is Fulcrum Therapeutics' stock symbol?
Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."
What price target have analysts set for FULC?
3 brokers have issued 1-year price targets for Fulcrum Therapeutics' shares. Their predictions range from $19.00 to $29.00. On average, they expect Fulcrum Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price. View Analyst Price Targets for Fulcrum Therapeutics.
What is the consensus analysts' recommendation for Fulcrum Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulcrum Therapeutics.
Has Fulcrum Therapeutics been receiving favorable news coverage?
News headlines about FULC stock have trended positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fulcrum Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Fulcrum Therapeutics.
Who are some of Fulcrum Therapeutics' key competitors?
Some companies that are related to Fulcrum Therapeutics include Odonate Therapeutics (ODT), Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), Stoke Therapeutics (STOK), Omeros (OMER), Zymeworks (ZYME), Cara Therapeutics (CARA), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), ZIOPHARM Oncology (ZIOP), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), Emisphere Technologies (EMIS), Principia Biopharma (PRNB) and Homology Medicines (FIXX).
What other stocks do shareholders of Fulcrum Therapeutics own?
Who are Fulcrum Therapeutics' key executives?
Fulcrum Therapeutics' management team includes the folowing people:
- Dr. Robert J. Gould, CEO, Pres & Director (Age 64)
- Peter G. Thomson, VP of Fin. & Accounting
- Mr. Bryan E. Stuart, Chief Operating Officer (Age 43)
- Dr. Owen B. Wallace, Chief Scientific Officer (Age 50)
- Dr. Diego Cadavid, Sr. VP of Clinical Devel. (Age 53)
When did Fulcrum Therapeutics IPO?
(FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.
When does the company's quiet period expire?
Fulcrum Therapeutics' quiet period expires on Tuesday, August 27th. Fulcrum Therapeutics had issued 4,500,000 shares in its public offering on July 18th. The total size of the offering was $72,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of Fulcrum Therapeutics?
Shares of FULC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fulcrum Therapeutics' stock price today?
One share of FULC stock can currently be purchased for approximately $10.14.
How big of a company is Fulcrum Therapeutics?
What is Fulcrum Therapeutics' official website?
How can I contact Fulcrum Therapeutics?
Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-651-8851 or via email at [email protected]
MarketBeat Community Rating for Fulcrum Therapeutics (NASDAQ FULC)
MarketBeat's community ratings are surveys of what our community members think about Fulcrum Therapeutics and other stocks. Vote "Outperform" if you believe FULC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FULC will underperform the S&P 500 over the long term. You may vote once every thirty days.
